Lacosamide and myoclonic seizures: what is the risk of aggravation?
Sign Up to like & getrecommendations! Published in 2021 at "Neurologia i neurochirurgia polska"
DOI: 10.5603/pjnns.a2021.0008
Abstract: Lacosamide (LCM), a novel antiseizure medication (ASM), is believed to exert its anticonvulsant action through selective enhancement of slow inactivation of voltage-gated sodium channels. LCM is indicated for the treatment of focal seizures, and has… read more here.
Keywords: aggravation; lacosamide myoclonic; risk aggravation; seizures risk ... See more keywords